Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a vasodilator that may cause smooth muscle relaxation. Its exact mechanism of action is not fully understood but is thought to involve beta-adrenergic receptor stimulation.
## Primary Indications
* Peripheral vascular disease (e.g., arteriosclerosis obliterans, vasospastic disorders)
* Cerebrovascular insufficiency
## Adult Dosing
* **Peripheral Vascular Disease:** 10-20 mg orally 3 to 4 times daily.
* **Cerebrovascular Insufficiency:** 10-20 mg orally 3 to 4 times daily.
* Maximum daily dose is generally not specified but should be guided by efficacy and tolerability.
## Pediatric Dosing
No established pediatric dosing. Safety and efficacy have not been determined.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment. However, caution is advised in patients with significant cardiovascular disease.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride
* Children under 12 years of age (due to lack of safety data)
## Adverse Effects
* **Common:** Hypotension, flushing, dizziness, nausea, vomiting, abdominal distress, rash, weakness, palpitations.
* **Less Common:** Tachycardia, gastric irritation.
## Key Drug Interactions
* **Antihypertensives:** May potentiate hypotensive effects.
* **Other Vasodilators:** Additive hypotensive effects.
## Monitoring
* Blood pressure (especially at the start of therapy or with dose changes)
* Signs and symptoms of peripheral vascular disease improvement
* Patient's tolerance of the medication
## Clinical Pearls
* Isoxsuprine is not approved by the FDA for any indication.
* Its efficacy in treating peripheral vascular disease and cerebrovascular insufficiency is debated and not well-established by robust clinical trials.
* Administer with meals to minimize gastrointestinal upset.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the current prescribing information and institutional protocols for definitive guidance.*
